AMGLIDIA 6 mg/mL oral suspension
P160916J
Phase 2 small_molecule active
Quick answer
AMGLIDIA 6 mg/mL oral suspension for Transient hyperglycaemia in premature infants is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Transient hyperglycaemia in premature infants
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active